Contineum Therapeutics, Inc. Class A Common Stock
- Open
- 16.37
- Day high
- 16.39
- Day low
- 15.41
- Prev close
- 16.39
- Volume
- 118K
- Mkt cap
- $580M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 2.3
- P/S
- —
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$166K over the last 3 months (0 open-market buys, 4 sales)
- 🏛Institutions accumulating (13F)
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is a Healthcare company listed on NASDAQ. The stock is up 326% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 4 sales (SEC Form 4).
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
CTNM earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 5, 2026 | $-0.55 | $-0.39 | +29.1% | — | — |
| Mar 5, 2026 | $-0.39 | $-0.49 | -26.0% | — | — |
| Oct 30, 2025 | $-0.58 | $-0.45 | +22.4% | — | — |
| May 14, 2025 | $-0.56 | $-0.62 | -10.7% | — | — |
| Mar 6, 2025 | $-0.44 | $-0.56 | -27.3% | — | — |
| Aug 13, 2024 | $-0.35 | $-0.39 | -11.4% | — | — |
| May 16, 2024 | $-0.46 | $-3.55 | -671.7% | — | — |
| Dec 30, 2023 | — | $-0.31 | — | — | — |
CTNM insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 26, 2026 | Miralles Gines Diegodirector | Grant | 19,000 | $14.19 |
| Jun 26, 2026 | Boyce Sarahdirector | Grant | 19,000 | $14.19 |
| Jun 26, 2026 | Brady Todd R.director | Grant | 19,000 | $14.19 |
| Jun 26, 2026 | Ignelzi Troy A.director | Grant | 19,000 | $14.19 |
| Jun 26, 2026 | Schimmelpennink Evert B.director | Grant | 19,000 | $14.19 |
| Jun 26, 2026 | Ware Olivia Cdirector | Grant | 19,000 | $14.19 |
| Jun 26, 2026 | Lyons-Williams Loridirector | Grant | 19,000 | $14.19 |
| Jun 1, 2026 | Lorrain Daniel S.officer: Chief Scientific Officer | Sell | 4,170 | $13.16 |
| May 1, 2026 | Lorrain Daniel S.officer: Chief Scientific Officer | Sell | 3,870 | $13.06 |
| May 1, 2026 | Lorrain Daniel S.officer: Chief Scientific Officer | Sell | 300 | $13.84 |
| Apr 6, 2026 | Lorrain Daniel S.officer: Chief Scientific Officer | Sell | 4,170 | $13.43 |
| Mar 2, 2026 | Watkins Timofficer: CMO & Head of Development | Option | 3,611 | $4.50 |
| Mar 2, 2026 | Watkins Timofficer: CMO & Head of Development | Sell | 3,611 | $15.02 |
| Mar 2, 2026 | Lorrain Daniel S.officer: Chief Scientific Officer | Sell | 4,170 | $15.01 |
| Feb 26, 2026 | Lorrain Daniel S.officer: Chief Scientific Officer | Sell | 3,824 | $16.01 |
Source: CTNM SEC Form 4 filings, latest Jun 26, 2026. For informational purposes only — not investment advice.
See the full CTNM insider & 13F page →Contineum Therapeutics, Inc. Class A Common Stock company profile
Overview
Contineum Therapeutics, Inc. (NASDAQ:CTNM) is a clinical-stage biopharmaceutical company founded in 2009 and headquartered in San Diego, California. Originally incorporated as Pipeline Therapeutics, Inc., the company rebranded to Contineum Therapeutics in November 2023. The company focuses on developing novel oral small molecule therapies targeting neurological, inflammatory, and immunological conditions with significant unmet medical needs. As a pre-revenue biotech firm, Contineum is advancing multiple drug candidates through various stages of clinical development, with its lead asset targeting both pulmonary fibrosis and multiple sclerosis.
Business
Contineum Therapeutics operates in the biotechnology sector, specifically developing oral small molecule drugs for complex medical conditions affecting the nervous system and immune system. The company's approach focuses on creating pills that patients can take by mouth, rather than injections or infusions, which represents a significant advantage for patient compliance and quality of life. The company's lead drug candidate is PIPE-791, a brain-penetrant small molecule that inhibits the lysophosphatidic acid 1 receptor (LPA1R). This drug targets two distinct conditions: idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (MS). IPF is a devastating lung disease where scar tissue progressively replaces healthy lung tissue, making breathing increasingly difficult. Progressive MS is a form of multiple sclerosis where neurological function steadily deteriorates over time. The LPA1R receptor plays a role in both the scarring process in lungs and the inflammation that damages nerve cells in the brain and spinal cord. PIPE-307 represents the company's second major program, designed as a selective inhibitor of the muscarinic type 1 M1 receptor. This drug candidate targets depression and relapsing-remitting multiple sclerosis. The M1 receptor is involved in cognitive function and mood regulation, making it an attractive target for treating depression while potentially offering neuroprotective benefits for MS patients. The company's third program, CTX-343, is a peripherally-restricted LPA1R antagonist, meaning it works outside the brain and central nervous system. This approach allows the company to target inflammatory conditions in other parts of the body while avoiding potential central nervous system side effects. All three programs represent the company's core focus on neuroscience, inflammation, and immunology, with the business model centered entirely on drug development rather than commercialized products.
Revenue model
As a clinical-stage biopharmaceutical company, Contineum Therapeutics currently generates no revenue from product sales, as evidenced by zero revenue reported across all recent quarters. The company operates on a research and development model typical of early-stage biotech firms, where value creation comes from advancing drug candidates through clinical trials toward eventual regulatory approval and commercialization. The company's future revenue model will likely depend on several potential pathways. Direct commercialization would involve bringing approved drugs to market and selling them to healthcare providers, hospitals, and patients through insurance reimbursement. Licensing agreements with larger pharmaceutical companies could generate upfront payments, milestone payments as drugs progress through development, and royalties on future sales. Strategic partnerships might provide development funding in exchange for co-commercialization rights or geographic licensing. The company's financial sustainability currently depends on raising capital through equity offerings, as demonstrated by the significant cash positions reported in recent quarters. Operating expenses primarily consist of research and development costs, including clinical trial expenses, manufacturing costs for drug supply, regulatory affairs, and personnel costs for scientific staff. Several factors could significantly impact the company's future profitability margins. Regulatory approval success rates represent the primary risk, as most drug candidates fail during clinical development. Competition from other companies developing treatments for the same conditions could limit market share and pricing power. Healthcare reimbursement policies will determine how much payers are willing to cover for new treatments. Manufacturing scale and complexity will influence production costs once drugs reach commercialization. Patent protection duration will determine how long the company can maintain exclusive market positions before generic competition emerges.
Competitive moat
Contineum Therapeutics operates in a highly competitive biotechnology landscape where sustainable competitive advantages are difficult to establish and maintain. The company's primary potential moat lies in its intellectual property portfolio surrounding its novel drug compounds and their specific mechanisms of action. Patents on PIPE-791, PIPE-307, and CTX-343 could provide temporary exclusivity periods if the drugs successfully reach market approval. The company's scientific expertise and specialized knowledge in LPA1R and M1 receptor biology represents another potential competitive advantage. Understanding these complex biological pathways and having experience in developing drugs that target them creates institutional knowledge that competitors would need time to replicate. The brain-penetrant properties of PIPE-791, which allows it to cross the blood-brain barrier effectively, may represent a technical achievement that provides differentiation from competing approaches. However, the company's moat position appears relatively weak for several reasons. High failure rates in drug development mean that even promising compounds may never reach commercialization, rendering any competitive advantages moot. Large pharmaceutical companies possess significantly greater resources for research and development, manufacturing capabilities, and regulatory expertise, allowing them to potentially develop competing therapies more rapidly. Academic institutions and other biotech companies are actively researching similar biological targets, creating the risk that alternative approaches or superior compounds could emerge. The company faces particular vulnerability in the multiple sclerosis market, where numerous established treatments already exist and major pharmaceutical companies continue investing heavily in new therapies. In pulmonary fibrosis, while fewer treatment options exist, the relatively small patient population limits the overall market opportunity and may not justify the substantial investment required for drug development by larger competitors.
Risks & safety
Contineum Therapeutics presents a mixed margin of safety profile typical of clinical-stage biotechnology companies, with strong liquidity but significant cash burn and operational risks. • Cash position and liquidity: The company maintains a robust cash position with $22.5 million in cash and short-term investments as of Q1 2025, down from $77.2 million in Q2 2024, indicating substantial cash consumption during operations. • Cash burn analysis: Free cash flow burn averaged approximately $14.5 million per quarter in recent periods, suggesting the current cash position provides roughly 1.5 years of operating runway at current spending levels without additional financing. • Debt and solvency: The company maintains minimal debt with a debt-to-equity ratio of 0.032, indicating low financial leverage. Current ratio of 21.5x demonstrates strong short-term liquidity coverage. • Valuation considerations: With no revenue generation, traditional valuation metrics are not applicable. The company trades at approximately 0.98x book value, suggesting the market values the company close to its tangible net worth. • Operational risks: As a pre-revenue company burning cash at $58 million annually (based on 2024 full-year free cash flow), the primary solvency risk stems from the need for continued capital raising to fund operations and clinical trials. The biotechnology sector's high failure rates create additional uncertainty around the company's ability to generate future cash flows from its drug development programs.
Recent development
Based on the available financial data, Contineum Therapeutics has undergone significant corporate transformation over recent years. The most notable strategic development was the company's rebranding from Pipeline Therapeutics to Contineum Therapeutics in November 2023, suggesting a strategic repositioning or corporate restructuring. The company's financial trajectory shows a dramatic shift from 2023 to 2024. In 2023, the company reported unusual positive results with $50 million in revenue and $22.7 million in net income, which contrasts sharply with the typical pre-revenue biotech profile. This anomalous year likely reflects a significant one-time transaction, possibly related to asset sales, licensing agreements, or corporate restructuring activities associated with the rebranding. Operational scaling and cash management represent key strategic focuses, as evidenced by the company's substantial cash raise that peaked at over $77 million in Q2 2024. This capital infusion likely supports accelerated clinical development activities across the company's three main drug programs. The subsequent cash burn pattern suggests active clinical trial execution and expanded research and development operations. The company's research and development intensity has increased significantly, with quarterly cash burn rising from approximately $6-8 million in mid-2024 to over $14 million in recent quarters. This acceleration likely indicates progression of clinical trials to more expensive phases or expansion into additional indications for existing drug candidates. Strategic positioning appears focused on building a diversified pipeline across neuroscience and immunology indications, rather than concentrating resources on a single program. This approach spreads risk across multiple therapeutic areas while potentially creating more opportunities for partnership or acquisition interest from larger pharmaceutical companies.
CTNM company profile · for informational purposes only — not investment advice.
Track CTNM with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free